Cell and gene therapy companies trip at scalability hurdle
In the last few decades, the rise in cell and gene therapy development has brought about several high-profile successes, but…
24 Apr 2024
Social prescribing: friend or foe for pharma?
As the number of patients being diagnosed with mental health conditions, diabetes, and other chronic conditions increases, more primary care networks in the UK are utilising social prescribing as a…
11 Apr 2024
Drug delivery innovations push forth women’s health
From enhancing contraceptive methods to improving the treatment of reproductive health issues, drug delivery innovations are paving the way for a more personalised and effective approach to women's healthcare. Various…
04 Apr 2024
Harnessing pharmacovigilance to turn reactive investigation into active discovery
Pharmacovigilance uses science and action to detect, assess, understand and prevent adverse events (AEs) or other issues relating to medicines or vaccines. It is, therefore, a vital component in ensuring…
03 Apr 2024
Continuous monitoring expands aseptic knowledge and data in real time
Highlighted by the introduction of regulatory stipulation in August 2023, real-time monitoring for cleanrooms involves using particle counters and other devices to provide data on different parameters in a continuous…
02 Apr 2024
Can pharma overcome generative AI’s bias problem?
Generative artificial intelligence (AI) or gen AI refers to algorithms that can produce new content such as codes, text, images and simulations. Tools such as ChatGPT and chatbots provide an…
02 Apr 2024
Magazine: What’s next for AAV gene therapies in 2024?
As the number of specialised gene therapies continues to grow in the biotech sector, one particular subtype— those using adeno-associated virus (AAV) vectors—is becoming increasingly popular. In this month’s cover…